患有双相发作和晚期减少扩散的急性脑病症患者的脑病后的危险因素
Makoto Nishioka1, Mitsuo Motobayashi2, Tetsuhiro Fukuyama3
1Department of Medical Genetics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan; Division of Neuropediatrics, Nagano Children's Hospital, 3100 Toyoshina, Azumino 399-8288, Japan.
Brain & development
|December 19, 2023
概括
在双相发作和晚期减少扩散 (AESD) 的急性脑病变期间,氨酸胺转移酶 (ALT) 和酸胺转移酶 (AST) 水平升高表明患脑病后 (PEE) 的风险更高. 这一发现有助于在AESD患者中早期识别PEE风险.
科学领域:
- 儿科神经学 儿科神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 神经科学是一个神经科学.
背景情况:
- 脑病后 (PEE) 是急性脑病综合征后的一个显著并发症.
- 患有两相发作和晚期减少扩散 (AESD) 的急性脑病变的患者,与其他急性脑病变病例相比,PEE的发病率更高.
- 关于AESD急性阶段PEE的实验室风险因素的研究有限.
研究的目的:
- 确定与AESD相关PEE的发展相关的实验室风险因素.
- 分析AESD急性阶段的实验室参数,以预测PEE的发展.
主要方法:
- 对27名被诊断患有AESD的儿科患者进行了回顾性查.
- 招募了20名患者,分为PEE组 (n=6) 和非PEE组 (n=14).
- 对实验室发现的分析,特别是急性阶段的氨酸转移酶 (ALT) 和酸氨酸转移酶 (AST) 水平.
主要成果:
- 与AESD相关的PEE的发病率为30%,AESD后的中位数发病时间为2.5个月.
- 在66.7%患有PEE的患者中观察到可吸收性.
- 与非PEE组相比,在PEE组中发现ALT水平 (第一和第二次发作阶段) 和AST水平 (第二次发作阶段) 的中位数显著更高 (p < 0.01).
结论:
- 在AESD急性阶段血清ALT和AST水平升高被确定为AESD相关PEE发展的新风险因素.
- 这项研究为与AESD相关的PEE的临床特征提供了关键的见解,与现有文献保持一致.
- 通过在AESD急性阶段监测ALT和AST水平,可以早期识别PEE风险.
相关概念视频
01:24Arteries of the Lower Limbs
191
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
191
01:13Seizures: Classification
372
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
372
01:20Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
413
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
413
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
310
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
310
01:14Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376